Psilocybin therapy is currently in phase three trials for treatment-resistant depression, while MDMA is ahead in the research timeline. A surge of studies is exploring various psychiatric disorders, revealing promising results in difficult-to-treat conditions. The shift in perception towards psychedelics as potential therapies marks a significant evolution in the understanding of mental health treatments, contrasting sharply with their historical stigma.
